Long-term efforts of the international community have led to the development of highly effective direct antiviral drugs (DAAs), which can actually cure the vast majority of patients with chronic hepatitis C. The targets of this type of drugs are proteins encoded in the genome of the hepatitis C virus (HCV), which play a key role in its life cycle: NS3, NS5A and NS5B. There are three classes of DAAs, each of which aims to inhibit a specific target protein. Since HCV has a high rate of accumulation of mutations, the biggest problem is the development of resistance to these drugs. The currently recommended DAA treatment regimens without the use of interferon and ribavirin are a combination of drugs of different classes that increase the barrier of resistance. In connection with the advent of DAAs, a number of WHO member countries, with the participation of Russia, put forward a global strategy for the eradication of hepatitis C. Considering the high cost of DAAs and the large number of HCV-infected people in Russia, achieving the goals declared by WHO presents great financial difficulties for our country. However, federal funds allocated to the treatment of hepatitis C have increased substantially over the past 3 years. In addition to increasing funding, there is great potential for reducing the cost of treatment, but its implementation is impossible without organizing national production of quality generics, issuing compulsory licenses (provided that it is impossible to negotiate licensing with patent holders) and / or negotiating price reductions in exchange for volumes (the experience of Australia and Portugal, for example). Anyway, Russia is facing an extremely important task to provide therapy for several million patients with hepatitis C in the coming years to get closer to the goal of eradicating HCV set by the international community.